These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23444927)

  • 1. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
    Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
    BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders.
    Liu HT; Chen CY; Kuo HC
    J Formos Med Assoc; 2010 Dec; 109(12):862-78. PubMed ID: 21195884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nerve growth factor as a biomarker in the diagnosis and treatment of overactive bladder (OAB)].
    Jankiewicz K; Kulik-Rechberger B; Nowakowski Ł; Rechberger T
    Ginekol Pol; 2012 Jul; 83(7):532-6. PubMed ID: 22880479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
    Liu HT; Chancellor MB; Kuo HC
    BJU Int; 2009 Jun; 103(12):1668-72. PubMed ID: 19220267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment.
    Liu HT; Kuo HC
    Urology; 2008 Jul; 72(1):104-8; discussion 108. PubMed ID: 18400272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
    Kim SR; Moon YJ; Kim SK; Bai SW
    Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers in overactive bladder.
    Bhide AA; Cartwright R; Khullar V; Digesu GA
    Int Urogynecol J; 2013 Jul; 24(7):1065-72. PubMed ID: 23314226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of nerve growth factor levels in overactive bladder syndrome: alterations after botulinum toxin therapy].
    Knippschild S; Frohme C; Olbert P; Hofmann R; Hegele A
    Urologe A; 2012 Mar; 51(3):379-83. PubMed ID: 21979907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis.
    Sheng W; Zhang H; Ruth KH
    Neurourol Urodyn; 2017 Sep; 36(7):1703-1710. PubMed ID: 28102552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome.
    Silva-Ramos M; Silva I; Oliveira O; Ferreira S; Reis MJ; Oliveira JC; Correia-de-Sá P
    PLoS One; 2013; 8(5):e64696. PubMed ID: 23741373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.
    Kuo HC; Liu HT; Chancellor MB
    Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder.
    Yokoyama T; Kumon H; Nagai A
    Neurourol Urodyn; 2008; 27(5):417-20. PubMed ID: 17924444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: a meta-analysis.
    Qu HC; Zhang W; Yan S; Liu YL; Wang P
    PLoS One; 2014; 9(9):e106321. PubMed ID: 25181532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
    Liu HT; Chancellor MB; Kuo HC
    Eur Urol; 2009 Oct; 56(4):700-6. PubMed ID: 18472208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary nerve growth factor in children with overactive bladder: a promising, noninvasive and objective biomarker.
    Oktar T; Kocak T; Oner-Iyidogan Y; Erdem S; Seyithanoglu M; Ziylan O; Kocak H
    J Pediatr Urol; 2013 Oct; 9(5):617-21. PubMed ID: 22789557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder.
    Ciftci S; Ozkurkcugil C; Yilmaz H; Ustuner M; Yavuz U; Yuksekkaya M; Cekmen MB
    Int Urogynecol J; 2016 Feb; 27(2):275-80. PubMed ID: 26310546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
    Liu HT; Lin H; Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary Nerve Growth Factor Can Predict Therapeutic Efficacy in Children With Overactive Bladder.
    Fukui S; Aoki K; Morizawa Y; Miyake M; Fujimoto K
    Urology; 2017 May; 103():214-217. PubMed ID: 28161379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome.
    Beta A; Giannouli A; Rizos D; Mantzou A; Deligeoroglou E; Bakas P
    Int Urogynecol J; 2024 Jun; 35(6):1317-1322. PubMed ID: 38761233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome.
    Kuo HC; Liu HT; Guan Z; Tyagi P; Chancellor MB
    Low Urin Tract Symptoms; 2011 Apr; 3(1):2-9. PubMed ID: 26676344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.